Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)

Trial Details

NCT ID
NCT06321484
Phase
PHASE1
Sponsor
Dana-Farber Cancer Institute
Status
RECRUITING
Cancer Type
Clear Cell Ovarian Cancer
Interventions
  • Cytokine-Induced Memory-like Natural Killer Cells
  • Interleukin 2
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must have histologically or cytologically confirmed recurrent epithelial ovarian cancer. Eligible histologies include high grade serou…
  • Participants must have measurable cancer defined by RECIST 1.1 criteria.
  • Patients must have received at least 1 lines of prior systemic therapy and be deemed platinum resistant/intolerant by their treating oncologist. Pa…
  • Age ≥18 years and \<85 years old.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Ovarian Cancer Trials on Trialify →